Eduardo M Netto

Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials.

Wayne Greaves, J. Slim, M. Nelson, 2012, The Journal of infection.